Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study

被引:252
作者
Greenberg, GR
Feagan, BG
Martin, F
Sutherland, LR
Thomson, ABR
Williams, N
Nilsson, LG
Persson, T
机构
[1] UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA
[2] UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA
[3] UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON,CANADA
[4] UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA
[5] UNIV CALGARY,DEPT COMMUNITY HLTH SCI & MED,CALGARY,AB,CANADA
[6] UNIV ALBERTA,DEPT MED,EDMONTON,AB,CANADA
[7] DALHOUSIE UNIV,DEPT MED,HALIFAX,NS,CANADA
[8] ASTRO DRACO AB,DEPT CLIN RES & DEV,LUND,SWEDEN
[9] ASTRO DRACO AB,DEPT BIOSTAT & DATA PROC,LUND,SWEDEN
[10] UNIV ALBERTA HOSP,EDMONTON,AB T6G 2B7,CANADA
[11] ROYAL ALEXANDRA HOSP,EDMONTON,AB,CANADA
[12] UNIV BRITISH COLUMBIA HOSP,VANCOUVER,BC,CANADA
[13] VICTORIA GEN HOSP,HALIFAX,NS B3H 2Y9,CANADA
[14] ST PAULS HOSP,VANCOUVER,BC V6Z 1Y6,CANADA
[15] UNIV CALGARY,FOOTHILLS HOSP,CALGARY,AB,CANADA
[16] CALGARY GEN HOSP,CALGARY,AB,CANADA
[17] HALIFAX INFIRM,HALIFAX,NS,CANADA
[18] UNIV LAVAL,HOP ST FRANCOIS DASSISE,QUEBEC CITY,PQ G1K 7P4,CANADA
[19] HOP HOTEL DIEU,QUEBEC CITY,PQ,CANADA
[20] MCGILL UNIV,JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA
[21] MONTREAL GEN HOSP,MONTREAL,PQ H3G 1A4,CANADA
[22] MCMASTER UNIV,FAC HLTH SCI,HAMILTON,ON,CANADA
[23] UNIV MANITOBA,ST BONIFACE HOSP,WINNIPEG,MB,CANADA
[24] UNIV MONTREAL,HOP MAISONNEUVE ROSEMONT,MONTREAL,PQ,CANADA
[25] HOP ST LUC,MONTREAL,PQ H2X 1P1,CANADA
[26] CARLETON UNIV,OTTAWA CIVIC HOSP,OTTAWA,ON K1S 5B6,CANADA
[27] UNIV SASKATCHEWAN,ROYAL UNIV HOSP,SASKATOON,SK,CANADA
[28] PASQUA HOSP,REGINA,SK,CANADA
[29] ST MICHAELS HOSP,TORONTO,ON M5B 1W8,CANADA
[30] SUNNYBROOK MED CTR,TORONTO,ON,CANADA
[31] TORONTO GEN HOSP,TORONTO,ON,CANADA
[32] WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA
[33] UNIV WESTERN ONTARIO HOSP,LONDON,ON N6A 5A5,CANADA
[34] ST JOSEPHS HOSP,HAMILTON,ON,CANADA
[35] ASTA PHARMA INC,TORONTO,ON,CANADA
关键词
D O I
10.1053/gast.1996.v110.pm8536887
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Budesonide is a corticosteroid with high topical anti-inflammatory activity and low systemic activity due to rapid hepatic metabolism, The efficacy and safety of an oral controlled-release preparation of budesonide for maintenance of remission was evaluated in patients with ileal or ileocecal Crohn's disease, Methods: In a double-blind, multicenter trial, 105 patients were randomly assigned to receive placebo or budesonide at doses of 3 or 6 mg daily for 1 year, The primary outcome measure was relapse defined by a Crohn's Disease Activity Index score of >150 and a minimum increase of 60 points, Results: Patients receiving 6 mg of budesonide had a median time to relapse or discontinuation of therapy of 178 days compared with 124 days in those receiving 3 mg of budesonide and 39 days in those receiving placebo. However, at 1 year, the rate of relapse in the group receiving 6 mg of budesonide was similar to the rates in the 3 mg and placebo groups, Basal plasma cortisol levels and incidence of corticosteroid-associated effects were similar in the three groups, Conclusions: Oral controlled-release budesonide (6 mg/day) was well tolerated and prolonged remission in Crohn's disease of the ileum and proximal colon, but this effect was not sustained at 1-year follow-up.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 21 条
[1]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[2]  
Brattsand R., 1990, Can J Gastroenterol, V4, P407
[3]   BUDESONIDE - AN UPDATED REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, AND THERAPEUTIC EFFICACY IN ASTHMA AND RHINITIS [J].
BROGDEN, RN ;
MCTAVISH, D .
DRUGS, 1992, 44 (03) :375-407
[4]  
DAHLBERG E, 1984, MOL PHARMACOL, V25, P70
[5]  
EDSBACKER S, 1993, GASTROENTEROLOGY, V104, pA695
[6]   ORAL MESALAMINE (PENTASA) AS MAINTENANCE TREATMENT IN CROHNS-DISEASE - A MULTICENTER PLACEBO-CONTROLLED STUDY [J].
GENDRE, JP ;
MARY, JY ;
FLORENT, C ;
MODIGLIANI, R ;
COLOMBEL, JF ;
SOULE, JC ;
GALMICHE, JP ;
LEREBOURS, E ;
DESCOS, L ;
VITEAU, JM ;
RENE, E ;
METMAN, EH ;
BORIES, P ;
BREMONDY, A ;
BOUVRY, M ;
LAMOULIATTE, H ;
GINESTON, JL .
GASTROENTEROLOGY, 1993, 104 (02) :435-439
[7]   ORAL BUDESONIDE FOR ACTIVE CROHNS-DISEASE [J].
GREENBERG, GR ;
FEAGAN, BG ;
MARTIN, F ;
SUTHERLAND, LR ;
THOMSON, ABR ;
WILLIAMS, CR ;
NILSSON, LG ;
PERSSON, T ;
BAIN, V ;
CHERRY, R ;
FEDORAK, R ;
LALOR, E ;
SHERBANIUK, R ;
YACYSHYN, B ;
KIERDEKIS, P ;
BAILEY, R ;
MEYER, D ;
FREEMAN, H ;
DAWS, P ;
HOLLAND, S ;
BUYTENDORP, M ;
WHITTAKER, S ;
CHANG, A ;
SUTHERLAND, L ;
HERSHFIELD, N ;
MACCANNELL, K ;
MEDDING, J ;
PRICE, L ;
SHAFFER, E ;
RACICOT, N ;
BASS, S ;
BRIDGES, R ;
BLUSTEIN, P ;
LAY, T ;
VANROSENDAAL, G ;
WATSON, M ;
WILLIAMS, CN ;
VANZANTEN, V ;
LEDDIN, D ;
FALKENHAM, J ;
TANTON, R ;
HUMAN, P ;
TURNBALL, G ;
SCHEP, G ;
WOOLNOUGH, J ;
DALLAIRE, C ;
ROSSEAU, B ;
BERNARD, F ;
DUBE, R ;
PARE, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :836-841
[8]  
GREENBERGER NJ, 1994, LANCET, V334, P901
[9]   A NEW MEASURE OF HEALTH-STATUS FOR CLINICAL-TRIALS IN INFLAMMATORY BOWEL-DISEASE [J].
GUYATT, G ;
MITCHELL, A ;
IRVINE, EJ ;
SINGER, J ;
WILLIAMS, N ;
GOODACRE, R ;
TOMPKINS, C .
GASTROENTEROLOGY, 1989, 96 (03) :804-810
[10]   QUALITY-OF-LIFE - A VALID AND RELIABLE MEASURE OF THERAPEUTIC EFFICACY IN THE TREATMENT OF INFLAMMATORY DOWEL DISEASE [J].
IRVINE, EJ ;
FEAGAN, B ;
ROCHON, J ;
ARCHAMBAULT, A ;
FEDORAK, RN ;
GROLL, A ;
KINNEAR, D ;
SAIBIL, F ;
MCDONALD, JWD ;
VALBERG, B ;
LAUPACIS, A ;
RIDDELL, R ;
SEATON, T ;
SOMERS, S ;
DIRKS, J ;
FEUTREN, G ;
JEEJEEBHOY, K ;
SACKETT, D ;
DANDAVINO, R ;
GHENT, CN ;
GRYNOCH, JR ;
HOLBROOK, AM ;
KIBERD, BA ;
KNETEMAN, N ;
LEVINE, M ;
MANUEL, M ;
MUIRHEAD, NN ;
SAIPHOO, CS ;
SOMERVILLE, PJ ;
CAMERON, L ;
LOCKWOOD, T ;
SEGLENIEKS, E ;
TAYLORDOLMER, K ;
CHERRY, R ;
FISHER, D ;
KIRDEIKIS, P ;
MAHACHAI, V ;
SEDENS, T ;
SHERBANIUK, R ;
THOMSON, A ;
WENSEL, R ;
CASTELLI, M ;
COLLINS, S ;
CROITORU, K ;
CROWE, S ;
DONNELLY, M ;
GOODACRE, R ;
HUNT, R ;
LUMB, B ;
ROSSMAN, R .
GASTROENTEROLOGY, 1994, 106 (02) :287-296